Pfizer Saudi Limited signed an exclusive commercial agreement with Tabuk Pharmaceuticals. The deal will permit Pfizer to advertise and promote branded and high-value generic drugs, such as medicines that provide treatment for kidney dialysis, kidney transplant, urology, and the central nervous system. This agreement is part of a larger Vision 2030 effort to strengthen local manufacturing capabilities. Pfizer started production at a $50 million plant in Saudi Arabia in January.
Pfizer Signs Commercial Agreement
You also might be interested in
G20 Saudi Arabia 2020 Logo The G20 Digital Economy Taskforce held two consecutive meetings on[...]
The following is a summary of all announcements from the[...]
The Saudi Industrial Development Fund (SIDF) announced a $1 billion stimulus package[...]